Cargando…

Evaluation of efficacy and safety of PARP inhibitors in breast cancer: A systematic review and meta-analysis

BACKGROUND: Many breast cancer clinical trials with PARPi have been completed or are currently carried out, either by monotherapy or combined with chemotherapy. We aim to assess the efficacy and safety of PARPi in breast cancer patients as compared to chemotherapy. METHODS: A comprehensive literatur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Xiao-Fei, Ren, Xiao-Lu, Yang, Jie-Quan, Shi, Jian-Jun, Bai, Jun-Heng, Cui, Meng-Sheng, Dong, Wen-Wen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215282/ https://www.ncbi.nlm.nih.gov/pubmed/34130011 http://dx.doi.org/10.1016/j.breast.2021.05.009

Ejemplares similares

Efficacy and safety of PARP inhibitors in patients with BRCA-mutated advanced breast cancer: A meta-analysis and systematic review
por: Sun, Ximu, et al.
Publicado: (2021)

Efficacy and Safety of PARP Inhibitors in Advanced or Metastatic Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
por: Liu, Xu, et al.
Publicado: (2021)

Efficacy and Safety of PARP Inhibitor Combination Therapy in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis
por: Ren, Ning, et al.
Publicado: (2021)

Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials
por: Shao, Fengping, et al.
Publicado: (2020)

PARP Inhibitors in Breast and Ovarian Cancer
por: Wang, Samuel S. Y., et al.
Publicado: (2023)

PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival
por: Shao, Fengping, et al.
Publicado: (2021)

Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
por: Wang, Hongmei, et al.
Publicado: (2021)

Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer
por: Jiang, Yifan, et al.
Publicado: (2020)

Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis
por: Maiorano, Brigida Anna, et al.
Publicado: (2022)

Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy
por: Chen, Zheling, et al.
Publicado: (2021)

Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer
por: Huang, Xuan-zhang, et al.
Publicado: (2020)

Incidence and risk of hypertension associated with PARP inhibitors in cancer patients: a systematic review and meta-analysis
por: Chen, Xiu, et al.
Publicado: (2023)

Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy
por: Valabrega, Giorgio, et al.
Publicado: (2021)

Venadaparib Is a Novel and Selective PARP Inhibitor with Improved Physicochemical Properties, Efficacy, and Safety
por: Lee, Myongjae, et al.
Publicado: (2023)

The safety and efficacy of PDE5-inhibitors-vardenafil on treating diabetes mellitus erectile dysfunction: A protocol for systematic review and meta analysis
por: He, Jia, et al.
Publicado: (2019)

The Efficacy and Safety of Enoxaparin: A Meta-analysis
por: Hai-long, Wang, et al.
Publicado: (2018)

Comparative Efficacy and Safety of PARP Inhibitors as Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
por: Xu, Yangchun, et al.
Publicado: (2021)

An Overview of PARP Inhibitors for the Treatment of Breast Cancer
por: Cortesi, Laura, et al.
Publicado: (2021)

Efficacy of PARP Inhibitor, Platinum, and Immunotherapy in BRCA-Mutated HER2-Negative Breast Cancer Patients: A Systematic Review and Network Meta-Analysis
por: Sun, Wanyi, et al.
Publicado: (2023)

PARP inhibitors
por: Anwar, Maheen, et al.
Publicado: (2015)

PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications
por: Zhu, Heng, et al.
Publicado: (2020)

Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting
por: Wu, Zhaozhen, et al.
Publicado: (2021)

PARP inhibitors: enhancing efficacy through rational combinations
por: Bhamidipati, Deepak, et al.
Publicado: (2023)

Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-mutated HER2-negative metastatic or advanced breast cancer: a network meta-analysis
por: Wang, Ju, et al.
Publicado: (2020)

The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis
por: Yang, Yingzhu, et al.
Publicado: (2020)

EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer
por: Yamaguchi, Hirohito, et al.
Publicado: (2017)

Efficacy and safety of calcineurin inhibitor treatment for IgA nephropathy: a meta-analysis
por: Song, Yu-Huan, et al.
Publicado: (2017)

Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma
por: Yang, Fei, et al.
Publicado: (2022)

The efficacy and safety of infliximab and calcineurin inhibitors in steroid-refractory UC patients: A meta-analysis
por: Zhao, Heng-Nan, et al.
Publicado: (2021)

Advances in the use of PARP inhibitor therapy for breast cancer
por: McCann, Kelly E, et al.
Publicado: (2018)

PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer
por: Curtin, Nicola, et al.
Publicado: (2020)

Efficacy and safety of short duration radiotherapy combined with chemotherapy for advanced rectal cancer
por: Gao, Shu-Quan, et al.
Publicado: (2021)

PARP inhibitor re-sensitizes Adriamycin resistant leukemia cells through DNA damage and apoptosis
por: Wu, Jie, et al.
Publicado: (2019)

Design and synthesis of benzodiazepines as brain penetrating PARP-1 inhibitors
por: Yu, Jiang, et al.
Publicado: (2022)

Efficacy and Safety of Acupuncture for Essential Hypertension: A Meta-Analysis
por: Chen, Hao, et al.
Publicado: (2018)

PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities
por: Sim, Hao-Wen, et al.
Publicado: (2022)

PARP inhibitors: the race is on
por: Brown, Jessica S, et al.
Publicado: (2016)

Safety profile of poly (ADP-ribose) polymerase (PARP) inhibitors in cancer: a network meta-analysis of randomized controlled trials
por: Bao, Shengnan, et al.
Publicado: (2021)

Combination Treatment Strategies to Overcome PARP Inhibitor Resistance
por: Soung, Young-Hwa, et al.
Publicado: (2023)

Design, Synthesis, and In Vitro Evaluation of the Photoactivatable Prodrug of the PARP Inhibitor Talazoparib
por: Li, Jiaguo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mur1kjh9bh64nupi9vt3uk2l6f